EIA directed against toxin A are appealing assays because they test for the toxin traditionally thought most responsible for pathogenicity. They are also more rapid and less expensive than the cytotoxicity assay. However, EIA for the detection of toxin A, although used in some clinical laboratories, have been subject to criticism for a demonstrated lack of correlation with the cytotoxicity assay and other laboratory methods. Most problematic has been the EIA's lack of sensitivity compared to the cytotoxicity assay.6"' Clinical and therapeutic parameters possibly related to false negative EIA results have not been studied previously.
tinal microflora that can cause diarrhoea and pseudomembranous colitis following disruption of the normal microbial environment.
Pathogenic strains of C difficile produce toxin A and toxin B, present together in virtually all cases. Toxin A was originally considered an enterotoxin and was thought to be largely responsible for human disease; toxin B was initially termed a cytotoxin due to its characteristic cytopathic effect when incubated with various cell lines in culture. Recent models of C difficile colitis recognise the enteropathic, cytopathic, and probable synergistic effects of both toxins A and B.' Both toxins have been cloned and sequenced; they have been shown to share 64% sequence homology.4 I The diagnosis of C diffiile colitis relies on clinical parameters, such as diarrhoea and recent antibiotic use, and laboratory confirmation. There is no consensus on whether detection of toxin A or toxin B is a more appropriate indicator of a patient's disease status. The most sensitive routine laboratory test is cell culture assay for cytotoxicity, thought to rely largely on the presence of toxin B. Recently, enzyme immunoassays (EIA) directed against both toxins have been developed and evaluated."' EIA directed against toxin A are appealing assays because they test for the toxin traditionally thought most responsible for pathogenicity. They are also more rapid and less expensive than the cytotoxicity assay. However, EIA for the detection of toxin A, although used in some clinical laboratories, have been subject to criticism for a demonstrated lack of correlation with the cytotoxicity assay and other laboratory methods. Most problematic has been the EIA's lack of sensitivity compared to the cytotoxicity assay.6"' Clinical and therapeutic parameters possibly related to false negative EIA results have not been studied previously.
In this study, we evaluated a new one hour EIA method for toxin A detection; it is designed for use with an automated analyser and includes a new blocking step designed to eliminate indeterminate results. We also investigated the nature of discrepant results between the EIA for toxin A and the traditional cytotoxicity assay. We hypothesised that toxins A and B are subject to different mechanisms of test interference, perhaps related to identifiable clinical parameters. We speculated that the presence of antibiotics, including standard treatment for C difficile, in the specimen may affect the results of the two tests differently.
Materials and methods

SPECIMENS
Specimens included consecutive diarrhoeal stool samples sent to our laboratory for C difficile cytotoxicity assay from 6 May to 19 June and from 26 July to 18 September 1996. Included were samples from hospitalised patients in our 750 bed tertiary care hospital and from outpatients at several affiliated clinics. Quality of the stool specimen, if lipaemic or mucous, was recorded. In addition to performing the cytotoxicity assay as is standard in our laboratory, we performed an additional EIA for toxin A on each specimen. All assays were performed on freshly collected stool specimens on the day of receipt unless the specimen was received after 1230, in which case it was refrigerated overnight and tested the next day. Specimens collected on Saturdays after 1230 were refrigerated until Monday. The refrigeration policy was in accordance with the manufacturers' instructions for both assays. Rockland, Massachusetts, USA) analyser in accordance with the manufacturer's instructions for the Vidas C difficile Toxin A II Assay. The Vidas analyser was used to perform an automated enzyme linked fluorescence assay using a solid phase receptacle (SPR) coated with polyclonal rabbit antitoxin A antibody. Supernatant, mouse monoclonal antitoxin A antibody, antimouse antibody conjugated with alkaline phosphatase, and 4-methylumbelliferyl phosphate were sequentially cycled in and out of the SPR. A fluorescent product, 4-methylumbelliferone, was catalysed by enzyme remaining bound within the SPR. Fluorescence intensity was measured by the analyser's optical scanner. Reference standards were processed in parallel. For specimens with fluorescence intensity over 10 000 times the reference, the assay was repeated with a blocking step-the supernatant was diluted 1/4 with sample diluent, added to 10 il of the manufacturer's blocking reagent, and again run on the Vidas analyser. Daily batches of tests were performed in runs that took approximately 11/2 hours each. Blocking steps took approximately 1 hour per specimen.
CLINICAL ASSESSMENT
Clinical data from this institution, including all admission notes, discharge instructions and summaries, and pharmacy and laboratory records, were reviewed for all patients with a positive cytotoxicity assay or toxin A EIA.
STATISTICAL ANALYSIS.
Fisher's exact test was used to obtain two sided p values. Confidence intervals (CI) were determined using the approximation of Woolf.
Results
Seven hundred and thirty seven stool samples were tested. Six hundred and seventy two (91%) were negative by both methods and 65 (9%) were positive by one or both methods. The 65 positive tests were samples from 56 patients. Of the 65 tests with positive results, 38 (58%) were positive by both test methods; 22 (34%) were positive by cytotoxicity assay and negative by EIA for toxin A. Five (8%) were negative by cytotoxicity assay and positive by EIA. Using positive cytotoxicity as a gold standard for disease, the sensitivity of the EIA was 62.2%, and the specificity was 99.3% (tables 1 and 2).
The blocking method was required for 22 (3%) of the 737 samples studied. Blocking was performed for eight cytotoxicity positive cases and yielded a positive result in three (sensitivity, 38%). Blocking was performed for 14 cytotoxicity negative cases and yielded a positive result in one specimen (specificity, 93%).
PRIOR AND FOLLOW UP TESTING
Of the 60 samples with positive cytotoxicity tests, 22 (37%) came from patients previously tested by cytotoxicity assay at this hospital; 13 specimens (nine EIA positive and four EIA negative) came from patients who had previous positive cytotoxicity assays. Three of seven (43%) EIA positive samples from patients Two of the five specimens falsely positive by EIA were from patients on antibiotics concurrent with testing; both were on ofloxacin and intravenous vancomycin.
SPECIMEN PROCESSING
Of the 60 samples with positive cytotoxicity assays, eight were refrigerated at least overnight before testing. This included three EIA positive samples and five EIA negative samples. Of these eight cases with a delay between receipt and testing, one was EIA positive immediately, three required blocking, and four were immediately negative; thus, one (3%) of 35 immediately EIA positive samples and seven (28%) of 25 samples not immediately positive were refrigerated (p = 0.007; odds ratio, 0.07563; 95% CI, 0.008615 to 0.6639). Only one of the seven samples not immediately EIA positive was from a patient on antibiotics (ofloxacin) at the time of specimen receipt.
Of the cytotoxicity positive/EIA positive samples, four were mucous and one was lipaemic. Of the cyotoxicity positive/EIA negative samples, one was mucous and one was lipaemic.
One of the five specimens falsely positive by EIA was refrigerated overnight.
PATIENT DEMOGRAPHICS
The male:female ratio was 17:21 in patients with cytotoxicity positive/EIA negative specimens and 11:1 1 in patients with specimens falsely negative by EIA. Patients with cytotoxicity positive/EIA positive specimens had an average age of 61 and patients with false negative specimens had an average age of 64. Among specimens positive by cytotoxicity, six were from outpatients, including two with EIA positive specimens and four with EIA negative specimens. Eleven patients with cytotoxicity positive/EIA positive specimens were admitted with C difficile associated disease (as an admitting diagnosis or determined after study to be the cause of admission); three patients with cytotoxicity positive/EIA negative specimens were admitted with C difficile associated disease.
Discussion
Our results show that EIA has a high specificity for detecting toxigenic C difficile as defined by a positive cytotoxicity assay. The blocking step performed in our study eliminated indeterminate assays problematic in previous studies using this manufacturer's methods. 7 False negative EIA results were most common among patients not on current or recent antibiotic treatment for C difficile colitis. However, this relation was not significant (p = 0.15). We had speculated that false negative samples would be associated with concurrent anti-C difficile antibiotic use, due to different degradation rates of the two toxins after inhibition of toxin production in the specimen (as we have observed by adding vancomycin ex vivo to C difficile in continuous culture and showing that EIA turns negative before cytotoxicity testing; Vargas and Onderdonk, unpublished observations, 1996), yet no false negative EIA tests occurred among patients on standard therapy for C difficile within the seven days before testing. In our specimens positive by cytotoxicity assay, a delayed interval between specimen receipt and testing was associated with a false negative EIA result or an EIA requiring blocking in all but one case (p = 0.007). All except one of these specimens were from patients without concurrent antibiotic use, further refuting our hypothesis that false negative EIA results are caused by antibiotics in the stool. It is relevant that the sensitivity of EIA was not shown to be impaired by concurrent antibiotic treatment for C difficile.
Although, at our hospital, testing of specimens from patients already on such antibiotics occurred only in a small minority of patients, this practice is likely to continue, perpetuated by the current admission requirement by some long term care facilities of a negative laboratory test for C difficile.
Patients retested for C difficile associated disease were more commonly positive on their second cytotoxicity assay if they had tested cytotoxicity positive/EIA positive during our study than if they had tested cytotoxicity positive/EIA negative, suggesting that a negative EIA may indicate milder disease or predict a more rapid recovery. However, this interaction was not significant (p = 0.47). Study of clinical features distinguishing patients with discrepant from those with concordant EIA and cytotoxicity results was limited by available clinical data. Duration of diarrhoea and time of specimen collection were not well documented. Confounding factors in the clinical aspects of this study included the possibility that starting empiric C difficile treatment may be a marker for the severity or diagnostic certainty of the disease; also, a history of antibiotic use may be a marker for real disease.
The cytotoxicity assay is an imperfect gold standard for C difficile disease and our sensitivity and specificity results are thus limited. However, because cytotoxicity assay is quite sensitive and specific for the presence of C difficile toxin, we believe that it provides a practical comparison for evaluating the EIA. It is a particularly useful test for segregating patients into groups for analysis of clinical parameters that might affect the detection of toxin A versus toxin B. We conclude that, though rapid, specific, and free from indeterminate results, the new Vidas method of EIA for toxin A lacks sensitivity compared to cytotoxicity assay. Neither concurrent antibiotic treatment for C difficile nor any clinical feature examined in this study was associated with false negative EIA by this method.
